Cargando…

PB2136: PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC

Detalles Bibliográficos
Autores principales:	Schaff, L., Lobbous, M., Carlow, D., DeAngelis, L., Nabors, L. B., Grommes, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431396/ http://dx.doi.org/10.1097/01.HS9.0000851376.34315.4f

Ejemplares similares

COVD-23. PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC
por: Schaff, Lauren, et al.
Publicado: (2020)

Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study
por: Schaff, Lauren R., et al.
Publicado: (2022)

PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2
por: De La Fuente, A., et al.
Publicado: (2022)

Implementation of an Outpatient HD-MTX Initiative
por: Sokol, Kelsey, et al.
Publicado: (2022)

PB2136: THE VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN PREDICTING THE PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Glucarpidase to combat toxic levels of methotrexate in patients
por: Green, Jacalyn M
Publicado: (2012)

Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorin and glucarpidase
por: Connors, Nicholas J., et al.
Publicado: (2014)

Relationship Between the Free and Total Methotrexate Plasma Concentration in Children and Application to Predict the Toxicity of HD-MTX
por: Dong, Wei-Chong, et al.
Publicado: (2021)

LPTO-01. LEPTOMENINGEAL METASTASIS FROM OVARIAN CARCINOMA TREATED WITH SYSTEMIC HIGH-DOSE METHOTREXATE
por: Coffee, Elizabeth, et al.
Publicado: (2019)

ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL
por: Yamaguchi, Takashi, et al.
Publicado: (2019)

Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
por: Verkaaik, M, et al.
Publicado: (2011)

Update on Novel Therapeutics for Primary CNS Lymphoma
por: Schaff, Lauren R., et al.
Publicado: (2021)

Recovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapy
por: Harms, James, et al.
Publicado: (2017)

Monoclonal antibody targeting of methotrexate (MTX) against MTX-resistant tumour cell lines.
por: Affleck, K., et al.
Publicado: (1992)

Impairment of Methotrexate (MTX)‐Polyglutamate Formation of MTX‐resistant K562 Cell Lines
por: Koizumi, Shoichi
Publicado: (1988)

Consensus Guideline for Use of Glucarpidase in Patients with High‐Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance
por: Ramsey, Laura B., et al.
Publicado: (2017)

PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA
por: Soussain, C., et al.
Publicado: (2022)

PB2130: RATIONAL FOR METHOTREXATE USAGE FOR THE TREATMENT AND PREVENTION OF CNS INVOLVEMENT IN PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMAS.
por: Misyurina, A., et al.
Publicado: (2022)

Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort
por: Yerram, Prakirthi, et al.
Publicado: (2023)

2136 Frequently overlooked challenges of pragmatic trials
por: Kessler, Rodger S.
Publicado: (2018)

Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury
por: Heuschkel, Sandra, et al.
Publicado: (2021)

Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available
por: Rosales, Alejandra, et al.
Publicado: (2021)

Glucarpidase for Treating Adults with Delayed Methotrexate Elimination Due to Impaired Renal Function: An Economic Simulation Analysis
por: Kala, Jaya, et al.
Publicado: (2023)

Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy
por: Zhang, Jing, et al.
Publicado: (2020)

PB2347: THE ROLE OF UPFRONT LENALIDOMIDE MAINTENANCE FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS RESPONDING TO FIRST-LINE MTX TREATMENT
por: Zhang, Yan, et al.
Publicado: (2023)

Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia
por: Sari, Nur Melani, et al.
Publicado: (2021)

How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy
por: Taylor, Peter. C., et al.
Publicado: (2019)

Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World
por: Zhang, Le, et al.
Publicado: (2020)

Development of a population pharmacokinetics and pharmacodynamics model of glucarpidase rescue treatment after high-dose methotrexate therapy
por: Fukaya, Yutaka, et al.
Publicado: (2023)

Methotrexate (MTX) inhibition of cytokine production: relationship with clinical outcome and genetic polymorphisms
por: Sabina, P, et al.
Publicado: (2003)

MTXPK.org: A Clinical Decision Support Tool Evaluating High‐Dose Methotrexate Pharmacokinetics to Inform Post‐Infusion Care and Use of Glucarpidase
por: Taylor, Zachary L., et al.
Publicado: (2020)

PB2334: CENTRAL NERVOUS SYSTEM (CNS) RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA: CNS-SAMATYA RISK MODEL
por: Yokus, Osman, et al.
Publicado: (2023)

2136: Gut microbiome alterations in children undergoing hematopoietic stem cell transplantation
por: Qayed, Muna, et al.
Publicado: (2018)

Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
por: Saito, Shuntaro, et al.
Publicado: (2019)

GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
por: Vieira-Sousa, Elsa, et al.
Publicado: (2020)

Cashew Nut Shell Liquid (CNSL) as a Source of Drugs for Alzheimer’s Disease
por: Uliassi, Elisa, et al.
Publicado: (2021)

P1135: EFFECT OF GLUCARPIDASE RESCUE IN PATIENTS WITH HIGH-DOSE METHOTREXATE INDUCED ACUTE KIDNEY INJURY: A FRENCH PHARMACOVIGILANCE DATABASE STUDY
por: Pierre, Sabrina, et al.
Publicado: (2023)

2136. Rapid Antimicrobial Susceptibility Testing using ATP Luminescence and Machine Learning Methods
por: Kawabe, Shunsuke, et al.
Publicado: (2019)

Development of Sustainable Chemistry in Madagascar: Example of the Valuation of CNSL and the Use of Chromones as an Attractant for Mosquitoes
por: Ranarijaona, Miarintsoa Michaele, et al.
Publicado: (2021)

Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis
por: Katchamart, W, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_k1masagu4c8pa49skhote0nnci